Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sonnet BioTherapeutics, Inc.

Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Exposures Product Safety
Tickers SONN
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Exposures Product Safety
Tickers SONN
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Exposures Product Safety
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers SONN
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Exposures Product Safety
Tickers SONN
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Tickers SONN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.